STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Completed
- Human Immunodeficiency Virus (HIV)
- Ixazomib 1 MG
- +3 more
- Rochester, MinnesotaMayo Clinic
2021-12-08
Dec 8, 2021H
Recruiting
- Mantle Cell Lymphoma
- Ixazomib
- Busan, Western, Korea, Republic ofKosin University Gospel Hospital
2022-03-31
Mar 31, 2022D
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2022-03-15
Mar 15, 2022M
Active, not recruiting
- Solid Tumors
- Ixazomib
- Erlotinib
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2022-02-09
Feb 9, 2022P
Recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Ixazomib
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2022-02-28
Feb 28, 2022F
Active, not recruiting
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
- Ixazomib Citrate
- +2 more
- Seattle, WashingtonFred Hutchinson Cancer Research Center
2022-04-04
Apr 4, 2022Q
Recruiting
- Relapsing Remitting Multiple Sclerosis
- +2 more
- Ixazomib (NINLARO®) capsules / Matching placebo capsules
- London, Greater London, United KingdomRoyal London Hospital, Barts Health NHS Foundation Trust
2022-02-17
Feb 17, 2022E
Completed
- Glioblastoma
- Ixazomib
- Atlanta, GeorgiaEmory University/Winship Cancer Institute
2021-03-02
Mar 2, 2021E
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
- Atlanta, Georgia
- +3 more
2022-01-05
Jan 5, 2022U
Completed
- Kidney Diseases
- End Stage Renal Disease
- Ixazomib Oral Capsule
- Madison, WisconsinUniversity of Wisconsin Hospital and Clinics
2021-05-03
May 3, 2021T
Not yet recruiting
- Multiple Myeloma
- Ixazomib
- +3 more
- (no location specified)
2021-12-20
Dec 20, 2021E
Active, not recruiting
- Mantle Cell Lymphoma
- Ixazomib
- Rituximab
- Atlanta, Georgia
- +1 more
2021-10-26
Oct 26, 2021J
Active, not recruiting
- Myeloma
- Clarithromycin
- +3 more
- La Jolla, California
- +2 more
2022-03-14
Mar 14, 2022T
Completed
- Relapsed and/or Refractory Multiple Myeloma
- Ixazomib
- +2 more
- Tokyo, JapanTakeda Selected Site
2021-06-03
Jun 3, 2021A
Recruiting
- Kaposi Sarcoma
- Skin
- Ixazomib Citrate
- +2 more
- Los Angeles, California
- +1 more
2021-03-26
Mar 26, 2021M
Suspended
- Recurrent Waldenstrom Macroglobulinemia
- +2 more
- Ibrutinib
- +4 more
- Jacksonville, Florida
- +1 more
2021-08-02
Aug 2, 2021P
Active, not recruiting
- Mantle-Cell Lymphoma
- Ixazomib
- Ibrutinib
- Atlanta, Georgia
- +13 more
2022-03-31
Mar 31, 2022H
Terminated
- AML
- AML, Adult
- TAK-659
- Ixazomib
- Indianapolis, IndianaIndiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022M
Completed
- Myeloid Hematologic Malignancy
- Lymphoid Hematologic Malignancy
- Ixazomib
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-09-03
Sep 3, 2021T
Recruiting
- Multiple Myeloma
- No Intervention
- Hwasun-gun, Jeollanam-do, Korea, Republic of(unnamed)
2021-04-14
Apr 14, 2021M
M
Active, not recruiting
- Multiple Myeloma
- High Risk Smoldering Multiple Myeloma
- Ixazomib (MLN9708)
- Dexamethasone
- Basking Ridge, New Jersey
- +5 more
2021-11-15
Nov 15, 2021M
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- Plasma Cell Myeloma
- Ixazomib Citrate
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-08
Mar 8, 2022U
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +8 more
- Ixazomib Citrate
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021B
Active, not recruiting
- B Cell Lymphoma
- Lymphoma
- Ixazomib
- +2 more
- Cleveland, Ohio
- +1 more
2022-03-03
Mar 3, 2022